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Abstract
Background. A 1 cm margin seen at operation is typically the minimally acceptable margin for liver resections. Patients who
fail to achieve this margin are routinely treated with edge cryotherapy at our unit. This paper aims to assess the benefit of
edge cryotherapy on survival in patients with such suboptimal margins . Patients and methods. Between January 1990 and
February 2006, 608 patients underwent liver resection and/or cryotherapy for colorectal cancer metastases. All liver
resections were performed using the CUSA transection method. Data on marginal status were available for 398 patients.
Patient demographics, number and size of liver lesions, preoperative and postoperative carcinoembryonic antigen (CEA) ,
extent of liver resection, margin status, site and date of recurrence, date of last follow-up and death were examined. Results.
There were 175 patients in the R0 group (1 cm macroscopic and ]1 mm microscopic margin), 103 patients in the R1
group (1 cm macroscopic and B1 mm microscopic margin) and 120 patients in the R2 group (51 cm macroscopic
margin and received edge cryotherapy). After a median follow-up of 63 months, there were no significant difference between
the 5-year survival rates for R0, R1 and R2 (40%, 30% and 28%, respectively). Conclusion. As long as the surgical margin is
clear macroscopically, the microscopic margin width does not affect survival. In patients with suboptimal margins, the
addition of edge cryotherapy improves the prospect for long-term survival and may lower recurrence risk.
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Introduction
Liver metastases complicate 30% of colorectal cancers
[1,2]. Without treatment, the natural history for
patients with colorectal liver metastases is dismal,
with virtually no 5-year survivors [3,4]. Currently the
only potentially curative treatment is liver resection.
However, only a minority of patients undergoing liver
resection are able to achieve disease-free, long-term
survival [57]. In the past 15 years, series often
exceeding several hundred patients have reported
5-year survival rates of 2558% [1,5,812]. Numer-
ous authors have examined the prognostic indicators
for successful surgical treatment [1,810,1318] and
a surgical margin 1 cm has been identified as a
significant prognostic indicator. Cady et al. [15,16]
found that a 1 cm surgical margin has a 5-year
disease-free survival rate of 30%, and is the only
prognostic factor under the surgeon’s control. Many
other authors also advocate that a surgical margin
1 cm be used [10,14,15,1922].
Although this is a widely held belief among
surgeons, few reports have addressed the extent
of negative resection margin and survival data
[5,10,12,15]. Some centres believe that a potential
surgical margin of B1 cm should not be an absolute
contraindication to liver resection, as the survival rate
is comparable to that of 1 cm margin [12,2325]. A
recent multicentre study by Pawlik et al. [12] claimed
that the width of a negative surgical margin does not
affect survival or recurrence risk. That is, liver
resection should be performed if histologically com-
plete resection of all metastatic sites can be achieved
without mortality.
This has practical implications with regards to
patient selection for potentially curative resection,
and the extent of resection needed. At our centre,
cryotherapy is applied to the residual liver edge in all
patients with a macroscopically involved margin to
optimize patient selection for curative resection. We
believe that the liver parenchymal transection techni-
que is also important, as the use of the Cavitron
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ultrasonic surgical aspirator (CUSA) can potentially
lead to 1 cm destruction along the resection margin.
We have recently shown that the application of edge
cryotherapy to suboptimal liver resection margins
(51 cm) can achieve longer survival and lower local
recurrence rates [26]. The objective of this paper was
to further compare these data with those patients who
had optimal margins, and report our experience on
the benefit of edge cryotherapy on the survival of
patients with suboptimal surgical margins.
Patients and methods
All patients who had undergone liver resections for
colorectal liver metastases performed at the Liver Unit
of the Department of Surgery, St George Hospital
(University of New South Wales, Sydney, Australia)
were retrieved from the progressively collected liver
database. Only patients who had undergone their first
liver resection were included. From a database of
608 colorectal cancer patients with liver metastases,
505 patients were identified to have undergone liver
resection with curative intent during January 1990 to
February 2006. For this report we identified 398
patients who had margin status available, survived the
operation and had a curative resection.
All patients underwent preoperative screening to
exclude extrahepatic disease and to assess the extent
of liver disease by the senior author (D.L.M). These
included clinical examination, chest, abdominal and
pelvic computed tomography (CT) scans and bone
scans to exclude extrahepatic disease. Positron emis-
sion tomography (PET) scan was not routinely
available until 2002. CT arterial-portography ob-
tained during the portal venous phase following a
superior mesenteric angiography (abdominal angio-
CT) was performed to assess the number, volume and
localization of hepatic disease, and resectability. The
presence of extrahepatic disease does not contra-
indicate liver resection if it can be entirely removed
during a simultaneous or delayed resection. Measure-
ments of preoperative liver function and carcinoem-
bryonic antigen (CEA) level were performed.
Intraoperative ultrasound was performed to assess
the size, number and relationship of liver metastases to
vital structures, especially portal sheath and hepatic
veins. Liver transection was performed using an ultra-
sonic surgical dissector (Selector; Spembly, Andover,
UK). Adequacy of the resection was assessed by or
under direct supervision of the senior author, and edge
cryotherapy was applied to marginsB1 cm. Edge
cryotherapy was delivered with a liquid nitrogen-based
system by a plate or a cylindrical probe (5 or 9 mm
diameter), depending on the size of lesion. This was
done under ultrasound guidance to monitor ice-ball
formation and to ensure a 1 cm tumour clearance in all
planes. The aim was always to completely ablate or
resect all disease (Cryotech LCS 3000, Spembly or
Cryo 6 System, Erbe, Tu¨bingen, Germany) [27]. The
specimen was then sent to the histopathologist for
analysis.
Postoperative follow-up consisted of clinical exam-
ination and measurement of serum CEA every
3 months. Abdominal CT was performed every
3 months in CEA non-secretors (B5 ng/ml preopera-
tively). For patients who had a CEA rise or if there
was any clinical suspicion, CT and/or PET scans
were used for confirmation of recurrence. Patients
were followed up until 2 February 2006 or until death
occurred.
In patients who received edge cryotherapy (R2
group), adjuvant hepatic arterial chemotherapy (1 g
5-fluorouracil per 24 h for 4 days every 2 weeks) was
initiated within 1 month postoperatively. A minority
of patients who were privately insured received
5-fluro-deoxyuridine instead (0.18 mg/kg for 2 weeks
on and 2 weeks off). Intravenous chemotherapy was
not instituted until patients developed recurrent
disease [28].
Data obtained for each patient included patient
demographics, number and size of liver lesions,
preoperative and postoperative CEA, extent of liver
resection, surgical margin status, site of recurrence,
date of recurrence, date of last follow-up and date of
death. The extent of resection was classified as lobar
resection or less. This included patients who had right
or left lobectomy or segmental resection. Patients not
included had undergone either extended right or left
hepatectomy. The resection margin was defined as the
shortest distance from the edge of the tumour to the
line of resection. Macroscopic margins were deter-
mined by the senior author intraoperatively by bisect-
ing the tumour with the scalpel and measuring the
shortest distance from the tumour to the resection
edge. An involved margin was defined as the presence
of tumour at the line of resection. Microscopic margin
was determined by the histopathologist; an involved
margin was defined as the presence of tumour cells at
the line of resection or when the resection margin
was B1 mm.
Patients were divided into R0, R1 or R2 groups
according to their margin status. R0 was defined as
macroscopically and microscopically clear, with
margins of 1 cm and ]1 mm, respectively. R1 was
defined as macroscopically clear and microscopically
involved, with margins of 1 cm and B1 mm, re-
spectively. R2 was defined as macroscopically in-
volved or had B1 cm margin. All patients in the R2
group received edge cryotherapy (Figure 1).
Statistical analyses were performed using the SPSS
version 13.0 for Windows software. The x2 test was
used to compare categorical factors. One-way AN-
OVA was used for the comparison of difference in
means for continuous factors. Survival and disease-
free interval analysis were performed using the
KaplanMeier actuarial survival curves and com-
pared using the log-rank test. A p value of B0.05
was considered to be significant.
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Results
The clinical features for the 398 patients are depicted
in Table I. There were 175 patients in the R0 group,
103 patients in the R1 group and 120 patients in the
R2 group. The R1 group had significantly more
lesions, and the R2 group had significantly larger
lesions. The R0 group had significantly less extensive
liver resections and had longer follow-up. For the
diagnosis of liver metastases, there were 38 (22%)
synchronous and 104 (59%) metachronous liver
metastases in the R0 group, 24 (23%) synchronous
and 67 (65%) metachronous liver metastases in the
R1 group, and 27 (23%) synchronous and 68 (57%)
metachronous diagnosis liver metastases in the R2
group. These data were not available for 70 patients.
In the R0 group, 28 (16%) patients had one and
8 (4.6%) patients had 2 subsequent liver resections.
In the R1 group, 19 (19%) patients had one and
4 (3.9%) patients had 2 subsequent liver resections.
In the R2 group, 23 (19%) patients had one and
7 (5.8%) patients had 2 subsequent liver resections.
These were not significantly different between the
groups (p0.663). After a median follow-up of
63 months (range 0.7170 months), 258 (65%)
patients developed recurrence. The median time to
any recurrence was 8 months (range 0.794 months),
and there was no significant difference between the
three groups. In all, 171 (43%) patients had liver
recurrence, with the median time to recurrence being
8 months (range 0.785 months). A total of 149
(37%) patients had extrahepatic recurrence, and the
median time to recurrence was 10 months (range
0.794 months). There was no significant difference
between the groups for either liver or extrahepatic
recurrence. In all, 199 (50%) patients had died by the
last follow-up. The median duration to death was
22 months (range 0.1107 months). The longest
living patient survived 140 months and is still alive
398 patients 
R0
Macroscopically:
Microscopically:
Margin status:   ≥ 1 mm
R2R1
Clear
Clear
Clear Involved or < 1 cm 
Clear or involvedInvolved
< 1 mm Edge cryotherapy
Figure 1. Patients were divided into three groups according to their
margin status. All patients in the R2 group received edge cryother-
apy.
Table I. Comparison of patient characteristics in the three margin status groups.
Variable R0 R1 R2 p value
Number of patients 175 103 120
Number of lesions 2 (111) 3 (114) 2 (19) B0.001
CI 2.052.62 CI 3.114.17 CI 2.072.67
Size of largest lesion (cm) 4 (0.216) 4 (0.519) 5 (118) 0.012
CI 4.035.04 CI 4.876.63 CI 4.936.10
Preoperative CEA (ng/ml) 10.8 (018885) 16.0 (04514) 17.3 (04360) 0.789
CI 4.50472.40 CI 73.58300.07 CI 56.04241.65
Postoperative CEA (ng/ml) 1.35 (086) 1.60 (0780) 2.00 (0402) 0.102
CI 2.505.36 CI 0.3632.87 CI 4.2821.15
Lobar resection or less 158 (90%) 86 (83%) 94 (78%) 0.001*
Number of patients with recurrence 106 (61%) 69 (67%) 83 (69%) 0.283*
Median time to recurrence (months) 9 (1.163) 7 (0.751) 9 (2.194) 0.059
CI 10.6114.73 CI 7.4512.02 CI 11.0917.95
Number of patients alive 99 (57%) 57 (55%) 41 (34%) B0.001*
Time to last follow-up (months) 60 (0.7168) 41 (0.8170) 88 (2.1165) B0.001
CI 58.9772.04 CI 43.1359.53 CI 77.7594.06
Number of patients with liver recurrence 61 (35%) 51 (50%) 59 (49%) 0.415*
Time to liver recurrence (months) 9 (242) 7 (0.743) 9 (2.185) 0.287
CI 4.9314.39 CI 6.6211.20 CI 9.8917.49
Number of patients with extrahepatic recurrence 62 (35%) 44 (43%) 43 (36%) 0.426*
Time to extrahepatic recurrence (months) 12 (1.163) 6 (0.751) 12 (2.194) 0.191
CI 12.2419.24 CI 18.0714.91 CI 11.6719.54
Numbers are median values. The range or percentage is denoted in parentheses. CI, confidence interval. *x2 values. Significant p values are
highlighted in bold type.
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and well. The 30-day mortality rate was 1.26% (five
patients). This included one patient in the R0 group,
one patient in the R1 group and three patients in the
R2 group. The causes of death were necrotizing
pancreatitis resulting in multiple organ failure, pan-
creatic abscess requiring drainage and resulting in
disseminated sepsis and multiple organ failure, ex-
tensive retroperitoneal necrosis and sepsis, ventricular
fibrillation arrest on a background of ischaemic
cardiac disease, and asystolic cardiac arrest.
The 5-year overall survival and disease-free survival
for the three groups are presented in Tables II and III,
respectively. The median overall survival was 37
months (range 0.1137 months). The 5-year survival
for R0, R1 and R2 was 40%, 30% and 28%,
respectively. There was no significant difference in
survival between the three groups. The Kaplan
Meier actuarial survival curve is shown in Figure 2.
Within the R2 group with involved or B1 cm macro-
scopic margin, there was no significant difference in
survival whether the margin was microscopically clear
or involved (Figure 3). Overall 5-year survival for all
patients was 35). The median disease-free interval
was 9 months (range 0137 months). The 5-year
disease-free survival for R0, R1 and R2 was 22%,
12% and 19%, respectively (Figure 4). There was a
significant difference with R0 having the longest
disease-free survival. Within the R2 group, whether
the microscopically margin was clear or involved
had no significant difference in disease-free survival
(Figure 5).
Discussion
As liver resection is still the gold standard in achieving
long-term survival for colorectal liver metastases,
numerous attempts have been made to improve
patient selection and increase the percentage of
patients who would benefit from surgery. Tradition-
ally, extrahepatic and nodal disease, positive margin,
time from primary tumour treatment to diagnosis of
hepatic metastases, preoperative CEA level, and the
number and size of the metastases have been reported
to be independent predictors of survival after liver
resection [9]. However, even in patients with higher
risk of recurrence no treatment other than surgery can
provide long-term survivors. The trend is to be more
aggressive and increase the indication for surgical
resection of liver metastases [29]. Long-term survivors
have been reported in patients in whom surgery would
not have been performed some years ago. Of all the
factors, margin status is the only prognostic indicator
under the surgeon’s control. There have been numer-
ous reports identifying that a margin of 1 cm was a
significant prognostic factor [8,10,14,15,1922].
Cady et al. [15] found a doubling of recurrence
rates in patients with a positive margin and a sig-
nificantly higher rate of recurrence in patients
with B1 cm margin compared with that of patients
with a margin 1 cm.
An accurate assessment of the true margin can
be difficult. This is because the use of ultrasonic
Table II. Overall survival: comparison between the three margin status groups.
Group 1-year 3-year 5-year Median (months) Range (months) 95% CI
R0 89% 53% 40% 39 0137 26.9150.22
R1 80% 47% 30% 35 080 17.7151.07
R2 89% 50% 28% 37 0126 30.3643.48
Log rank test is 5.11. p0.0776, not significant.
Table III. Disease-free survival: comparison between the three margin status groups.
Status group 1-year 3-year 5-year
Median
(months) Range (months) 95% CI
R0 58% 28% 22% 15 0137 11.7417.85
R1 39% 16% 12% 10 081 5.9814.01
R2 50% 24% 19% 13 0126 8.5316.58
Log rank test is 7.48. p0.024, significant.
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Figure 2. Overall survival curves for R0, R1 and R2 groups.
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dissectors aspirates a portion of liver parenchyma
between the tumour and normal liver. In addition, the
friability of the liver makes the assessment of margin
difficult. An approximate margin from 1 mm to 1 cm
due to transection debridement would not be un-
reasonable. To account for this potential sampling
error due to inked margin analysis, we used 1 mm as
the cut-off point for a microscopically clear margin.
A surgical margin 1 cm can be hard to achieve at
times. Surgeons may need to remove major vascular
structures, such as the hepatic vein, with more liver
tissue for an adequate margin. Sometimes the extent
of margin has to be compromised in patients with
poor liver function [26]. In our series of 398 patients,
120 (30%) patients had B1 cm margin macroscopi-
cally and all subsequently received edge cryotherapy
(R2 group). The 5-year survival rates for R0, R1 and
R2 were 40%, 30% and 28%, respectively, and there
were no significant difference between the groups.
Interestingly, few authors have advocated that pro-
vided the margins were free of tumour, the width of
negative surgical margin had no significant effect on
survival (Table IV). In addition, Pawlik et al. [12] and
Jamison et al. [30] found that in patients with a
negative margin, there were no differences in survival
whether the margin was greater or less than 1 cm.
Compared with patients with a positive (i.e. involved)
surgical margin, patients with a negative surgical
margin had significantly better 5-year survival.
The R2 group consisted of patients where inade-
quate margin was apparent only after hepatic resec-
tion and cryotherapy was given to the residual liver
edge. These patients have similar survival rates to
patients with macroscopically clear margins. We have
previously demonstrated that the addition of edge
cryotherapy reduces local recurrence with satisfactory
survival and low risk of recurrence [26,31,32]. Even
in cases where complete resection is not possible the
addition of cryotherapy leads to improved survival
when compared with palliative care or alternative
strategies [27]. An edge recurrence-free survival of
95% has been reported in patients with margins
B1 cm and 86% in patients with involved margins
when cryotherapy had been applied to improve
clearance [33].
Another important factor is the use of CUSA, one
of the most popular devices that facilitate bloodless
liver transection. It employs a vibrating metal tip to
fragment tissue and then aspirates the debris through
the hollow centre of the tip [34]. It has been shown to
contribute to the increased safety of liver resections as
it leads to reduction in perioperative blood loss,
duration of operation, postoperative morbidity and
mortality, and postoperative hospital stay [3537].
Unfortunately, the role of the surgical dissectors in
altering the margin status has not been properly
addressed. As CUSA could destroy 1 cm along the
transection plane, this in effect converts the margin
status from R2 to R1, that is, from a suboptimal to
an optimal margin. It also provides a margin of safety
in the R1 or macroscopically clear group. This has
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Figure 4. Overall disease-free survival for R0, R1 and R2 groups.
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Figure 5. Disease-free survival curve for microscopically clear or
involved margins in the R2 group (log rank test is 0.01; p0.92, not
significant).
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Figure 3. Overall survival curve for microscopically clear or
involved margins within the R2 group (log rank test is 0.00;
p0.99, not significant).
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potential long-term implications for all liver resec-
tions, regardless of the primary malignancy.
Currently, 4580% of patients who undergo hepa-
tic resection for colorectal liver metastasis develop
recurrence [3841]. In patients with a surgical resec-
tion margin of B1 cm, a recurrence rate of up to 50%
has been reported [16]. Liver recurrence only oc-
curred in 12% of patients with a negative surgical
margin, while no patients with a positive microscopic
margin had survived disease-free beyond 20 months.
Our series showed a recurrence rate of 65% with no
significant difference in recurrence (intrahepatic or
extrahepatic) despite margin status. This means that
whether or not the margin was macroscopically or
microscopically involved, the use of CUSA and edge
cryotherapy can achieve long-term survival or even
cure.
There are a number of limitations to this paper. We
do not have complete data on staging and site of
primary colorectal cancer, time to diagnosis of liver
metastases and the relationship of major vessels to the
resection edge. Another limitation of this study is that
we did not perform a randomized control study on
patients with close margins, which will better eluci-
date the effectiveness of edge cryotherapy. We have
shown that 28% of patients with an involved or close
margin can survive long term following edge cryother-
apy. It is possible that some patients in the close group
would have survived long term without edge cryother-
apy; however, there have been no reports of long-term
survival for obviously involved margins in the absence
of ablation.
Conclusion
As long as the surgical margin is clear macroscopi-
cally, a margin of B1 cm is acceptable as the margin
width does not affect survival. Application of edge
cryotherapy to macroscopically involved margins can
result in a similar 5-year survival rate to microscopi-
cally clear margins. Edge cryotherapy is therefore an
effective addendum to liver resection, leading to
improved long-term survival and recurrence risk in
patients with suboptimal surgical margins.
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